Radiological Versus Clinical 1‐Year Outcomes of Dupilumab in Refractory CRSwNP : A Real‐Life Study
The Laryngoscope · 2024
DOI: 10.1002/lary.31238 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Laryngoscope, 2024. Verfasst von Francesco Giombi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Milan, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Nasal Polyps, Sinusitis, Rhinitis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Objective
To provide real‐life evidence on long‐term radiological changes in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) treated with dupilumab, and to assess possible differences between radiological and clinical results in terms of endoscopic findings and Patient‐Reported‐Outcomes (PROs).
Methods
Consecutive patients treated with dupilumab for recalcitrant CRSwNP were required to undergo CT scan at baseline (T0) and after 12 (T1) since first administration. A group of patients also performed CT scan at 52 weeks (T2) to assess long‐term outcomes. At each timepoint, patients underwent nasal endoscopy, assessment of Nasal‐Polyp‐Score (NPS), Lund‐Kennedy‐Score (LKS), and had to fill in the 22‐item Sinonasal‐Outcome‐Test (SNOT‐22) and Visual‐Analogue‐Scales (VAS) for sinonasal symptoms.
Results
In fifty‐three included patients, from T0 to T1 we detected a significant reduction in mean Lund‐Mackay score (LM), PROs (SNOT‐22, VAS) and endoscopic (NPS, LKS) scores ( p < 0.05). In the subset of patients that reached T2 ( n = 30), compared to T1, we observed a further significant decrease in mean LM, SNOT‐22, VAS, and NPS scores, but not in LKS ( p = 0.420). At T1, the highest improvement was observed in PROs (SNOT‐22: 56.26%), and polyp size (NPS: 49.83%). Conversely, between T1 and T2, sinus opacification was shown to be the most improved outcome (LM: 36.86%).
Conclusions
Our experience showed that poorly controlled CRSwNP patients treated with dupilumab experienced significant improvement in radiologic, endoscopic and clinical disease severity. While in the initial 3 months, PROs garnered attention for showing earlier effectiveness, radiological outcomes revealed sustained and gradual efficacy in a longer term. Level of Evidence Level 4. According to the Oxford Center for Evidence‐Based Medicine 2011 level of evidence guidelines, this non‐randomized retrospective cohort study is classified as level 4 evidence Laryngoscope , 134:2626–2633, 2024
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Humanitas University, Milan, Italy.
- Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Milan, Italy.
- Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
- Otorhinolaryngology Head & Neck Surgery Unit, Casa di Cura Humanitas San Pio X, Milan, Italy.
- Department of Diagnostic and Interventional Radiology, IRCCS Humanitas Research Hospital, Milan, Italy.
ORCID-Profile: Francesco Giombi, Gian Marco Pace
Zitieren
APA
Giombi, F., Pace, G. M., Nappi, E., Giunta, G., Muci, G., Pirola, F., Ferreli, F., Heffler, E., Paoletti, G., Giannitto, C., Mercante, G., Francone, M., Spriano, G., Canonica, G. W., & Malvezzi, L. (2024). Radiological Versus Clinical 1‐Year Outcomes of Dupilumab in Refractory CRSwNP : A Real‐Life Study. The Laryngoscope. https://doi.org/10.1002/lary.31238
Vancouver
Giombi F, Pace GM, Nappi E, Giunta G, Muci G, Pirola F, et al. Radiological Versus Clinical 1‐Year Outcomes of Dupilumab in Refractory CRSwNP : A Real‐Life Study. The Laryngoscope. 2024. doi:10.1002/lary.31238
BibTeX
@article{Giombi2024,
author = {Giombi, Francesco and Pace, Gian Marco and Nappi, Emanuele and Giunta, Gianmarco and Muci, Giovanna and Pirola, Francesca and Ferreli, Fabio and Heffler, Enrico and Paoletti, Giovanni and Giannitto, Caterina and Mercante, Giuseppe and Francone, Marco and Spriano, Giuseppe and Canonica, Giorgio Walter and Malvezzi, Luca},
title = {Radiological Versus Clinical 1‐Year Outcomes of Dupilumab in Refractory CRSwNP : A Real‐Life Study},
journal = {The Laryngoscope},
year = {2024},
doi = {10.1002/lary.31238}
}
EUVIMED